Health Canada Allows Phase IIa Clinical Trial in COVID-19 Patients with Respiratory Failure
NuvOx Pharma has received a “No Objection Letter” from Health Canada to proceed with a Phase IIa clinical trial of NanO2 in COVID-19 subjects with acute hypoxic respiratory failure (AHRF).
